An eating disorder, food allergy, swallowing difficulty, persistent nausea, or very low food intake
Because the medication is compounded to order, it can also be created in an oral form, which is easier and less painful to take than the injections
Patients whose BMI falls between 25 and 29.9 may still qualify if they have documented metabolic syndrome, sleep apnea, cardiovascular disease, or other obesity-related conditions
At doses of 1mg or below, MT-2 produces minimal gastrointestinal effects because it doesnt delay gastric emptying like GLP-1 agonists
These products are not intended for human consumption, veterinary use, therapeutic use, diagnostic use, or resale as consumer goods